Table 1.
Patient characteristics
| Characteristic | ||
|---|---|---|
| Age (yr) | 74 (68–79) | |
| Time since initial diagnosis (yr) | 5.4 (3.4–9.5) | |
| No. of [ 177 Lu]Lu-PSMA-I&T cycles | 4 (2–6) | |
| Pretherapeutic blood parameters | ||
| PSA, ng/mL (n = 184) | 71.5 (23.0-219.4) | |
| LDH, U/L (n = 183) | 251 (215-324.5) | |
| AP, U/L (n = 182) | 117 (73.3-213.3) | |
| Hb, g/dL (n = 186) | 11.9 (10.4–13.1) | |
| Prior systemic therapies | ||
| Abiraterone | 159 (84.6) | |
| Enzalutamide | 115 (61.2) | |
| 223Ra | 15 (8.0) | |
| Docetaxel | 131 (69.7) | |
| Cabazitaxel | 25 (13.3) | |
| Previous chemotherapy | 133 (70.7) | |
| Site of metastasis | ||
| Lymph nodes | 127 (67.6) | |
| Bone | 174 (92.6) | |
| Visceral, overall | 39 (20.7) | |
| Liver | 13 (6.9) | |
| Lung/Pleura | 20 (10.6) | |
| Adrenal | 10 (5.3) | |
| Brain | 2 (1.1) | |
| Baseline 18 F-flotufolastat PET parameters | ||
| Number of lesions (n) | 128 (41.0-239.0) | |
| TTV, mL | 394.1 (122.2-1125.9) | |
| ITLV, mL | 877.6 (255.7-2527.7) | |
| Highest SUVmax | 60.6 (36.9–98.0) | |
| Whole-body SUVmax | 13.9 (9.8–22.0) | |
| Whole-body SUVmean | 5.6 (4.8–7.2) | |
| Whole-body SUVpeak | 9.0 (6.3–14.0) | |
Data are reported as median (interquartile range) or n (%).177Lu = Lutiteum-177; PSMA = prostate-specific membrane antigen; PSA = prostate-specific antigen; LDH = lactate dehydrogenase; AP = alkaline phosphatase; Hb = hemoglobin; mCRPC = metastatic castration-resistant prostate cancer; 223Ra = Radium-223; 18F = Fluorine-18; PET = positron emission tomography; TTV = total tumor volume; ITLV = intensity-weighted lesion volume; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; SUVpeak = peak standardized uptake value